Skip to main content
Springer Nature Link
Log in

Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung

  • Research Article
  • Published:
Tumor Biology

Abstract

Inhibition of histone deacetylases (HDACs) is a promising new approach to the treatment of lung cancer therapy. The relation between HDAC3 expression and the clinicopathological characteristics of lung cancer is not well understood, however. We therefore addressed this issue in patients with adenocarcinoma of the lung. We used semi-quantitative real-time reverse transcription polymerase chain reaction and immunohistochemical analysis to assess expression of HDAC3 in tumor samples from 94 patients with adenocarcinoma of the lung. We then correlated levels of HDAC3 expression with known clinicopathological factors. The 5-year disease-free survival (5-DFS) rate among patients expressing high levels of HDAC3 was significantly poorer than among those expressing lower levels (P = 0.005; log-rank test). Multivariate Cox proportional hazard analyses revealed male (hazard ratio, 3.88; 95% CI, 1.70-9.39; P = 0.001), nodal metastasis N1 (hazard ratio, 6.39; 95% CI, 1.54-22.7; P = 0.013), N2 (hazard ratio, 6.36; 95% CI, 1.55-33.6; P = 0.009), and HDAC3 (hazard ratio, 3.06; 95% CI, 1.07-7.55; P = 0.037) to be independent factors affecting the 5-DFS rate. Strong tumoral expression of HDAC3 is an independent predictor of a poor prognosis in patients with adenocarcinoma of the lung.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Karagianni P, Wong J. HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene. 2007;26:5439–49.

    Article  CAS  PubMed  Google Scholar 

  2. Weichert W, Röske A, Niesporek S, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008;14:x1669–77.

    Article  CAS  PubMed  Google Scholar 

  3. Krusche CA, Wülfing P, Kersting C, et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat. 2005;90:15–23.

    Article  CAS  PubMed  Google Scholar 

  4. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer. 2004;112:26–32.

    Article  CAS  PubMed  Google Scholar 

  5. Sasaki H, Moriyama S, Nakashima Y, et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer. 2004;46:171–8.

    Article  PubMed  Google Scholar 

  6. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010;3:5.

    Article  PubMed  Google Scholar 

  7. Siegel D, Hussein M, Belani C, et al. Vorinostat in solid and hematologic malignancies. Journal of Hematology & Oncology. 2009;2:31.

    Article  Google Scholar 

  8. Cang S, Ma Y, Liu D. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. Journal of Hematology & Oncology. 2009;2:22.

    Article  Google Scholar 

  9. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol. 2000;184:1–16.

    Article  CAS  PubMed  Google Scholar 

  10. Ramalingam SS, Maitland ML, Frankel P, et al. (2010) Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol (in press).

  11. Ramalingam SS, Parise RA, Ramanathan RK, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res. 2007;13:3605–10.

    Article  CAS  PubMed  Google Scholar 

  12. Vansteenkiste J, Van Cutsem E, Dumez H, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs. 2008;26:483–8.

    Article  CAS  PubMed  Google Scholar 

  13. Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther. 2008;7:759–68.

    Article  CAS  PubMed  Google Scholar 

  14. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38–51.

    Article  CAS  PubMed  Google Scholar 

  15. Sobin L, Wittekind CH, editors. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002. p. 99–103.

    Google Scholar 

  16. Bendinelli P, Matteucci E, Maroni P, Desiderio MA. NF-kappaB activation, dependent on acetylation/deacetylation, contributes to HIF-1 activity and migration of bone metastatic breast carcinoma cells. Mol Cancer Res. 2009;7:1328–41.

    Article  CAS  PubMed  Google Scholar 

  17. Lf C, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 2001;293:1653–7.

    Article  Google Scholar 

  18. Grégoire S, Xiao L, Nie J, et al. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol. 2007;27:1280–95.

    Article  PubMed  Google Scholar 

  19. Hayashi A, Horiuchi A, Kikuchi N, et al. (2010) Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with down-regulation of E-cadherin. Int J Cancer (in press)

  20. Imre G, Gekeler V, Leja A, Beckers T, Boehm M. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res. 2006;66:5409–18.

    Article  CAS  PubMed  Google Scholar 

  21. Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, Hershberger PA. Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells. Int J Cancer. 2010;126:743–55.

    Article  CAS  PubMed  Google Scholar 

  22. Takami Y, Nakayama T. N-terminal region, C-terminal region, nuclear export signal, and deacetylation activity of histone deacetylase-3 are essential for the viability of the DT40 chicken B cell line. J Biol Chem. 2000;275:16191–201.

    Article  CAS  PubMed  Google Scholar 

  23. Longworth MS, Laimins LA. Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src. Oncogene. 2006;25:4495–500.

    Article  CAS  PubMed  Google Scholar 

  24. Escaffit F, Vaute O, Chevillard-Briet M, et al. Cleavage and cytoplasmic relocalization of histone deacetylase 3 are important for apoptosis progression. Mol Cell Biol. 2007;27:554–67.

    Article  CAS  PubMed  Google Scholar 

  25. Jin KL, Pak JH, Park JY, et al. Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol. 2008;19:185–90.

    Article  CAS  PubMed  Google Scholar 

  26. Selvaggi G, Scagliotti GV. Histologic subtype in NSCLC: does it matter? Oncology. 2009;23:1133–40.

    PubMed  Google Scholar 

  27. Chang TH, Szabo E. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res. 2002;8:1206–12.

    CAS  PubMed  Google Scholar 

  28. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005;45:495–528.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Not applicable and not declared.

Author information

Authors and Affiliations

  1. The Division of Thoracic Surgery, Breast and Endocrine Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita City, 010-8543, Japan

    Yoshihiro Minamiya, Takashi Ono, Hajime Saito, Naoko Takahashi, Manabu Ito, Satoru Motoyama & Junichi Ogawa

Authors
  1. Yoshihiro Minamiya
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Takashi Ono
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Hajime Saito
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Naoko Takahashi
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Manabu Ito
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Satoru Motoyama
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Junichi Ogawa
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Yoshihiro Minamiya.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Minamiya, Y., Ono, T., Saito, H. et al. Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Tumor Biol. 31, 533–539 (2010). https://doi.org/10.1007/s13277-010-0066-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-010-0066-0

Keywords